Public Companies
Awakn Loses Psychedeclics Chief, Gains New Treatment Clinics
The company also opened a new clinic in Norway.
The post Awakn Loses Psychedeclics Chief, Gains New Treatment Clinics appeared first on Green Market R…
Canada-based biotech firm Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) has lost its head of psychedelic medicine, but due to the loss, it gained full ownership in one of its clinics.
Dr. Ben Sessa resigned his position as head of psychedelic medicine at the company, effective April 13, Awakn disclosed in a press release. As part of the exit, Sessa is transferring his 49% ownership in Awakn Bristol Limited, with Awakn Clinics Bristol in England, to Awakn Life Sciences Inc., giving the company 100% ownership in the British psychedelics clinic.
In the same press release, Awakn announced that it had commenced treatments for alcohol use disorder with patients at a Manhattan facility run by Nushama Inc., one of Awakn’s licensing partners for its product line of Awakn Kare.
And on March 1, Awakn opened Awakn Clinics Trondheim in Norway for ketamine-assisted therapy. The opening marks the company’s fourth clinic globally and its second in Norway.
Awakn made headlines in February when the company was accused by OTC Markets group of running a stock promotion scheme, an allegation it denied.
The post Awakn Loses Psychedeclics Chief, Gains New Treatment Clinics appeared first on Green Market Report.
ketamine psychedelic therapy treatment clinics psychedelics otc awakn life sciences awakn-
Law & Regulation7 days ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psilocybin1 week ago
The Psychedelic Scene in Oaxaca, Mexico
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Psychedelics7 days ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials